GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Who doesn’t love a comeback story? Certainly not GSK, which has found a way to resuscitate its cancer treatment Blenrep as a ...

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

LONDON (dpa-AFX) - British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of ...

GSK (NYSE:GSK) shares snapped six straight sessions of gains, as the stock ended down 0.6% at $38.70 on Friday. The ...

CHMP gives positive opinions for new drugs from GSK, Roche & SpringWorks, including GSK's Blenrep, Roche's Itovebi & ...

The recommendation by the Committee for Medicinal Products for Human Use--also known as CHMP--follows the approval of Blenrep combinations by the U.K.'s Medicines and Healthcare products Regulatory ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...